---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-064445"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:57:58.709548+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Synlogic appoints Michael Jensen as CFO effective March 3, 2022

## Summary
- Michael Jensen named CFO; previously CFO at Intrinsic Therapeutics and Taconic Biosciences.
- Base salary $395K, bonus target 40%, option grant of 230K shares at $2.23, 30K RSUs.
- Employment agreement provides 6-month severance upon termination without cause or for good reason.
- Press release notes Synlogic on track to start Phase 3 study for PKU in H2 2022.

## SEC filing metadata
- accession: 0001193125-22-064445
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/0001193125-22-064445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/d291506d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-064445
- JSON: https://secwatch.observer/filing/0001193125-22-064445.json
- Plain text: https://secwatch.observer/filing/0001193125-22-064445.txt

## Key facts
- Executive change
  Michael Jensen was appointed as Chief Financial Officer at SYNLOGIC, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 3, 2022, Synlogic, Inc. (the “Company”) announced the appointment of Michael Jensen as Chief Financial Officer, effective March 3, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/0001193125-22-064445-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.